Precision medicine: From pharmacogenomics to pharmacoproteomics

Allison B. Chambliss, Daniel W. Chan

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.

Original languageEnglish (US)
Article number25
JournalClinical Proteomics
Issue number1
StatePublished - Sep 26 2016


  • Biomarker
  • Pharmacogenomics
  • Precision medicine
  • Proteomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'Precision medicine: From pharmacogenomics to pharmacoproteomics'. Together they form a unique fingerprint.

Cite this